

Supplementary legends

Figure S1. Relative expression level of TRIM11 thyroid cancer cell lines.

Figure S2. Pulldown assay reveals direct interaction between TRIM11 and YAP.

CAL62 cells transfected with Flag-TRIM11 were lysed and lysates incubated with GST-YAP or GST protein. The interacted TRIM11 was detected via western blot.

Figure S3. TRIM11 increases the mono-ubiquitinated YAP while decreases K11- and K48-dependent polyubiquitination on YAP protein. (A-I). HEK293 cells were

transfected with 2 μ g Myc-YAP plasmid, 0.5 μ g Flag-TRIM11 plasmids, and 0.5 μ g HA-K6, -K11, -K27, -K29, -K33, -K48, -K63, -K0 or -Ub plasmids. The cell extracts were immunoprecipitated with HA antibody. The specific polyubiquitinated and mono-ubiquitinated YAP were detected via western blotting analysis.

Figure S4. TRIM11 increases the mono-ubiquitinated YAP and decreases K11- and K48-dependent polyubiquitination on YAP protein via its RING domain.

(A-D). HEK293 cells were transfected with 2 μ g Myc-YAP plasmid, 0.5 μ g Flag-TRIM11 or its deletion mutant plasmids, and 0.5 μ g HA-K11, -K48, -K0 or -Ub plasmids. The cell extracts were immunoprecipitated with HA antibody. The specific polyubiquitinated and mono-ubiquitinated YAP were detected via western blotting analysis.

Figure S5. YAP depletion inhibits anaplastic thyroid cancer cell proliferation and migration. (A). YAP depletion inhibits the cell proliferation in anaplastic thyroid cancer cells. (B, C). Representative images of EdU assay of anaplastic thyroid cancer cells. (D). YAP depletion decreases clone formation capability of anaplastic thyroid cancer cells. (E). Wound-healing assay of anaplastic thyroid cancer cells. (F). Transwell migration assay of anaplastic thyroid cancer cells.

, P value < 0.05; **, P value < 0.01; *, P value < 0.001.*

Figure S6. TRIM11 regulates the anaplastic cancer cells response to chemotherapy. (A-C). CAL62 Cells expressing indicated constructs were treated with doxorubicin, and cell survival was determined. (D-F). KHM-5M Cells expressing indicated constructs were treated with doxorubicin, and cell survival was determined. (G). In vivo xenografts generated from CAL62 cells expressing an empty vector, TRIM11 or YAP-targeting shRNA and treated with doxorubicin.

Figure S1




Figure S2




Figure S3





Figure S4


A

	Flag	Flag-TRIM11	Flag-TRIM11ΔR	Flag-TRIM11ΔBB	Flag-TRIM11ΔCC	Flag-TRIM11ΔPS
HA-K11	+	+	+	+	+	+
Myc-YAP	+	+	+	+	+	+
MG132	+	+	+	+	+	+




B

	Flag	Flag-TRIM11	Flag-TRIM11ΔR	Flag-TRIM11ΔBB	Flag-TRIM11ΔCC	Flag-TRIM11ΔPS
HA-K48	+	+	+	+	+	+
Myc-YAP	+	+	+	+	+	+
MG132	+	+	+	+	+	+



C

	Flag	Flag-TRIM11	Flag-TRIM11ΔR	Flag-TRIM11ΔBB	Flag-TRIM11ΔCC	Flag-TRIM11ΔPS
HA-Ub	+	+	+	+	+	+
Myc-YAP	+	+	+	+	+	+
MG132	+	+	+	+	+	+



D

	Flag	Flag-TRIM11	Flag-TRIM11ΔR	Flag-TRIM11ΔBB	Flag-TRIM11ΔCC	Flag-TRIM11ΔPS
HA-K0	+	+	+	+	+	+
Myc-YAP	+	+	+	+	+	+
MG132	+	+	+	+	+	+




Figure S5




Figure S6

